Sumitovant Biopharma Ltd.

Sep 24, 2020

FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis

Jun 01, 2020

Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

May 29, 2020

Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

May 13, 2020

Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer

Apr 29, 2020

Sumitovant Biopharma Announces Publication of Myovant Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 Liberty Studies in Uterine Fibroids in Obstetrics & Gynecology

Apr 24, 2020

Sumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant Sciences